<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783753</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 514-003</org_study_id>
    <nct_id>NCT04783753</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects</brief_title>
  <official_title>A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, and Quinidine on the Pharmacokinetics and Safety of EDP-514 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-randomized, 3-part, open-label, drug-drug interaction (DDI) study to evaluate the effect&#xD;
      of itraconazole, carbamazepine, or quinidine on the PK and safety of EDP-514 in healthy adult&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Actual">July 9, 2021</completion_date>
  <primary_completion_date type="Actual">June 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of EDP-514 with and without coadministration with itraconazole</measure>
    <time_frame>up to 19 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of EDP-514 with and without coadministration with itraconazole</measure>
    <time_frame>19 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of EDP-514 with and without coadministration with carbamazepine</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of EDP-514 with and without coadministration with carbamazepine</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of EDP-514 with and without coadministration with quinidine</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of EDP-514 with and without coadministration with quinidine</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>up to 34 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>EDP-514 and Itraconazole interaction (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-514 and Carbamazepine interaction (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-514 and Quinidine interaction (Part 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-514</intervention_name>
    <description>Subjects will receive EDP-514 on Days 1 and 14</description>
    <arm_group_label>EDP-514 and Itraconazole interaction (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-514</intervention_name>
    <description>Subjects will receive EDP-514 on Days 1 and 23</description>
    <arm_group_label>EDP-514 and Carbamazepine interaction (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-514</intervention_name>
    <description>Subjects will receive EDP-514 on Days 1 and 8</description>
    <arm_group_label>EDP-514 and Quinidine interaction (Part 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Subjects will receive itraconazole QD for 14 days</description>
    <arm_group_label>EDP-514 and Itraconazole interaction (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepin</intervention_name>
    <description>Subjects will receive carbamazepine BID for 23 days</description>
    <arm_group_label>EDP-514 and Carbamazepine interaction (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinidine</intervention_name>
    <description>Subjects will receive quinidine BID for 8 days</description>
    <arm_group_label>EDP-514 and Quinidine interaction (Part 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  An informed consent document signed and dated by the subject.&#xD;
&#xD;
          -  Male and female subjects of any ethnic origin between the ages of 18 and 55 years,&#xD;
             inclusive&#xD;
&#xD;
          -  Female subjects who are heterosexually active and of childbearing potential must agree&#xD;
             to use two effective methods of contraception from the date of Screening until 30 days&#xD;
             after the last dose of EDP-514.&#xD;
&#xD;
          -  Screening body mass index (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50 kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant evidence or history of illness or disease&#xD;
&#xD;
          -  Pregnant or nursing females.&#xD;
&#xD;
          -  History of febrile illness within 7 days prior to the first dose of study drug or&#xD;
             subjects with evidence of clinically significant active infection.&#xD;
&#xD;
          -  A positive urine drug screen at Screening or Day -1.&#xD;
&#xD;
          -  Current tobacco smokers or use of tobacco products within 3 months prior to Screening.&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).&#xD;
&#xD;
             â€¢ Clinically significant laboratory abnormalities at screening or Day -1, as&#xD;
             determined by the Investigator (including but not limited to hypokalemia,&#xD;
             hypocalcemia, or hypomagnesemia for Part 3 participants).&#xD;
&#xD;
          -  History of regular alcohol consumption&#xD;
&#xD;
          -  Participation in a clinical trial within 30 days prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
        For Part 2 (Carbamazepine) participants:&#xD;
&#xD;
          -  Participants of Asian ancestry, given association of carbamazepine and severe rash&#xD;
             (Stevens Johnson Syndrome [SJS] and Toxic Epidermal Necrolysis [TEN]) with HLA-B 1502&#xD;
             in this population.&#xD;
&#xD;
          -  Platelets, white blood cell count or hemoglobin below the lower limit of normal, due&#xD;
             to reported incidence of agranulocytosis and aplastic anemia with carbamazepine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaceutical Research Association</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-drug interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Quinidine</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

